Polycythemia Vera Clinical Trial
Official title:
Clinical and Laboratory Characteristics of Polycythemia Vera
The study is observational, longitudinal, retrospective and prospective, on patients with PV. Patients with PV diagnosed from 2000 to 2023 according to WHO2017 criteria will be considered. The main purpose of the study is to determine the impact of clinical and laboratory characteristics of Polycythemia Vera on patients' prognosis, understood as long-term survival
The structured collection of data necessary for the evaluation of the objectives will take place through the creation of a specific electronic archive with an expected duration of 7 years, possibly extendable. The electronic archive may be used to review case histories and to obtain or confirm new scientific evidence on Polycythemia Vera. Patients will be followed and treated within the care pathway provided by normal clinical practice. The following elements will be considered in each patient: age, recent and remote pathological history, characteristics of PV onset, histological, cytogenetic and molecular investigations of diagnostic definition, medical therapies performed, type of response to the therapies performed, complications of these therapies and pathology. All useful data will be collected exclusively through consultation of outpatient medical records. The planned enrollment period is 60 months (January 2019-December 2023). The observation period of enrolled patients is at least 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05558696 -
A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)
|
Phase 2 | |
| Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
| Completed |
NCT02912884 -
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
|
||
| Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
| Completed |
NCT01949805 -
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
|
Phase 3 | |
| Completed |
NCT00666549 -
Research Tissue Bank
|
||
| Completed |
NCT00241241 -
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
|
Phase 2 | |
| Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05485948 -
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
|
Phase 2 | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT01243944 -
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
|
Phase 3 | |
| Recruiting |
NCT05481151 -
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
|
Phase 3 | |
| Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT04116502 -
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
|
Phase 3 | |
| Completed |
NCT01901432 -
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04262141 -
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
|
Phase 2 | |
| Not yet recruiting |
NCT05566535 -
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
|
||
| Active, not recruiting |
NCT04057040 -
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
|
Phase 2 | |
| Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
| Completed |
NCT01981850 -
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
|
Phase 2 |